Ikarian Capital, LLC Reata Pharmaceuticals Inc Call Options Transaction History

Ikarian Capital, LLC

9 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q2 2023 Aug 14, 2023	BUY	$79.22 - $105.37 $792,200 - $1.05 Million	10,000 Added 10.0%	110,000 $11.2 Million
Q1 2023 May 15, 2023	BUY	$30.85 - $93.17 $3.09 Million - $9.32 Million	100,000 New	100,000 $9.09 Million
Q3 2022 Nov 14, 2022	SELL	$19.41 - $36.49 $463,899 - $872,111	-23,900 Reduced 14.75%	138,100 $3.47 Million
Q2 2022 Aug 12, 2022	BUY	$20.71 - $36.5 $3.04 Million - $5.35 Million	146,700 Added 958.82%	162,000 $4.92 Million
Q1 2022 May 13, 2022	SELL	$24.12 - $39.6 $4.45 Million - $7.31 Million	-184,700 Reduced 92.35%	15,300 $502,000
Q4 2021 Feb 14, 2022	BUY	$25.61 - $110.96 $2.32 Million - $10 Million	90,400 Added 82.48%	200,000 $5.27 Million
Q3 2021 Nov 15, 2021	SELL	$100.0 - $143.02 $750,000 - $1.07 Million	-7,500 Reduced 6.4%	109,600 $11 Million
Q3 2020 Nov 16, 2020	SELL	$93.53 - $163.34 $4.68 Million - $8.17 Million	-50,000 Reduced 29.92%	117,100 $11.4 Million
Q2 2020 Aug 14, 2020	BUY	$126.3 - $176.56 $21.1 Million - $29.5 Million	167,100 New	167,100 $26.1 Million

62.7K

Ticker RETA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 31,583,200
Description
Reata Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, identifies, develops, and commercializes novel therapeutics for patients with serious or life-threatening diseases. The company is developing Phase 3 clinical trial programs, including bardoxolone methyl (bardoxolone) for the treatment of patients with chronic kidney diseas...

Get notified when there are updates to the investment portfolio of Ikarian Capital, LLC, based on Form 13F filings with the SEC.

Stay updated on Ikarian Capital, LLC with notifications on news.